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The use of a screening strategy based on human tumor cell lines, which are also tumorigenic
in immune-deprived mice, is described. Activity against the human tumor cells in w.ro and in
vivo, is complemented with studies on the mechanism of action. This aporoach is
demonstrated using 2-[(dimethylamino)-methyl]phenyl (damp) gold(Ill) compounds of the
type [Au X2(damp)], where X chloride, thiocyanate, acetate, or the bidentate ligands
oxalate and malonate. All compounds were shown to be selectively active against a human
bladder tumor cell line (HT1376) in vitro, and active in an in vitro panel of ovarian tumor cell
lines. The acetato complex was shown to be active in experimental animal models of both
the HT1376 bladder tumor, and the CH1 ovarian tumor. Although the [AuX2(damp)]
compounds share structural features in common with cisplatin, and exhibit interesting in vivo
activity against human tumor cells, the data indicate that they have a very different
biochemical mechanism from platinum-based drugs and represent a potentially new class of
metal-based antitumor agents.
Introduction: An Historical Perspective
Strategies for identifying new anticancer agents have developed and evolved over the years
from simple animal models to the incorporation of the latest techniques in molecular
biology. Historically however these strategies have been predominantly based on in vivo
rodent tumor models. The earliest rodent models that were used, prior to 1955, were
allogeneic transplantable tumors such as Sarcoma 180, Erlich ascites, Yoshida ascites
sarcoma, and the Walker 256 carcinoma. These tumors are rapidly growing, undifferentiated
cell types. Being allogeneic the host animal will frequently mount an immune response to
the tumor, also the solid tumors such as Sarcoma 180 are frequently sensitive to host weight
loss. Both of these factors make it difficult to differentiate drug effect from host effects. In
addition some of these tumors such as the Erlich ascites are very sensitive to cytotoxic agents
thus leading to large numbers of false positives in the screen.
As a result of these limitations the allogeneic tumor models were superseded by syngeneic
transplantable murine tumors such as the L1210 and P388 leukemia’s, and the Lewis Lung
carcinoma, and B16 melanoma. These tumors retain their histologic type on transplantation,
grow rapidly and reproducibly, and give reproducible results with control drugs, therefore
satisfying many of the requirements of a screening system. They have been used extensively
by many laboratories for the pre-clinical selection of new antitumor agents.
One of the most well documented screening programs has been that of the American
National Cancer Institute. Between 1955 and 1975 their primary screening system consisted
of the L1210 and P388 leukemia’s, supplemented with other rodent tumors including the B16
melanoma and the Lewis Lung carcinoma. In 1975 they introduced a two-tier system to
broaden the number of tumor types against which new agents could be screened. This
involved a pre-primary screen using the P388 leukemia followed by a primary tumor panel
including murine tumors and human xenografts. This was used until 1990 with a few
variations on the theme. In spite of the inclusion of other tumor models in the screening
panel in practice the majority of compounds were only screened against the murine
leukemias. The outcome of this screening strategy was the discovery of a number of agents
that were successfully introduced into the clinic for the treatment of leukemias. There was,
however, only limited success in identifying agents for the treatment of the most commonly
occurring, major solid tumors of lung, breast and colon. The NCI experience has been
reflected in that of other cancer institutes and laboratories worldwide.
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Table 1 Historical. summary of cancer drug s,,c,,reening
YEAR PRIMARY SCREEN SECONDARY SCREEN
-i5i:----5 Aiiogeneic transplantaisle"murin tumors.
Sarcoma 180
Erlich Ascites
Yoshida ascites sarcoma
Walker 256 carcinoma
1955 Walker 256 carcinoma
Syngeneic transplantable murine tumors:
L1210 leukemia
1968 L1210 murine leukemia
P388 murine leukemia
M urineumo?s-
L1210 leukemia
B16 melanoma
Lewis lung
Xenografts:
..M:__!__.,__.._g.- !._,______LX:!
P388 leukemia Murine tumors:
L1210, B16, M5076, LL
rafls MX-1
1990 Re-evaluation
B16 melanoma
Lewis !_u_ng carcinoma
1975 P388 leukemia
1982
Alternative Strategies
The limited success in identifying agents for the treatment of solid tumors led to a major re-
evaluation of screening strategies for new cancer drugs. One possible explanation proposed
for this failure was the predominant use of murine leukemias as a primary screen. There are
two major limitations to the murine leukemias as tumor models. One is that the cancer cells
and test drug are in close proximity. The leukemia cells are grown as ascitic suspensions in
the peritoneal cavity of the host animal and test compounds are usually administered directly
into the peritoneal cavity, whereas in contrast solid tumors are distant from the site of drug
administration. In consequence in these simple ascitic models there is no need to take into
account the barriers a drug has to face in reaching its target, both in terms of distribution and
metabolism. Secondly, being a mouse leukemia, the cell type is not typical of a human solid
tumor, which will have different characteristics and susceptibilities to drugs. This latter
problem has been the focus of attention in a number of laboratories, including the NCI. They
have adopted a system based on panels of human tumor-derived cell lines. This is a disease
oriented approach utilising a panel of 60 cell lines derived from commonly occurring tumors
including melanomas, leukemias, breast, prostrate, lung, colon, ovary, kidney, and central
nervous system.
4 These cell lines are therefore representative of the different histologic types
of many solid tumors. The hypothesis is that compounds with selective activity against cell
lines of a particular tissue type would be predictive for activity against the corresponding
tumor. The cell lines are challenged in vitro with the test agent and cell growth monitored
using a colorimetric assay which measures total cell protein using an aminoxanthene dye,
sulforhodamine B. The activity of test compounds is compared to that of known agents with
defined mechanisms of action using a computer programme called COMPARE. The
concept is still being evaluated as compounds progress through to clinical trials however it is
becoming apparent that this approach is proving to be particularly useful in providing
valuable insight into drug mechanism, and molecular targets within cancer cells.SA similar
approach has been adopted by the EORTC in Europe,3 the Institute of Cancer Research in
the UK,
6 and our own laboratory.
These are of course in vitro systems and therefore do not predict for the in vivo behaviour of a
drug such as its pharmacokinetics, metabolism, or toxicity. An alternative to using in vivo
murine cancers is to use xenografts of human cancer cells transplanted into immune-
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deprived mice. Many of the cell lines used in the in vitro panels described above can be
grown as xenografts, therefore compounds selected in the in vitro screen can be further
evaluated in vivo against the same tumor cells. Usually the tumor cells are implanted
subcutaneously in the flank of the host animal where a solid tumor will form and grow. The
test drug can then be administered by a number of routes. The intraperitoneal route is the
most common route for drug screening, but compounds can also be administered orally or
intravenously as appropriate. The effect of drug on tumor growth is monitored over a suitable
time period, usually a minimum of 28 days.
An alternative to screening compounds in tumor models is to evaluate compounds against
particular molecular and cellular targets,
a This mechanistic approach to drug discovery can
take a number of forms, depending upon the target. Cell signalling pathways responsible for
transmitting information from the outside of a cell to the nucleus have become the research
focus for a number of laboratories. Many of the proteins and enzymes implicated in these
pathways are encoded by oncogenes, a typical example being the receptor-mediated
tyrosine kinases. Many cancer drugs kill cancer cells by triggering programmed-cell death or
apoptosis. The intracellular events responsible for controlling apoptosis are being studied
with the view to gaining an understanding of how these events can be exploited in the
development of new drugs. Other molecular targets include key enzymes in DNA metabolism
and repair, and DNA itself.
One of the major problems facing oncologists is the spread of primary solid tumors to distant
sites leading to the establishment of secondary tumors. This spread of tumors throughout the
body, is a multi-step process, and is known as metastasis. Part of this process involves
degradative enzymes including metalloproteases, cysteine proteases and the serine
proteases.
9 These enzymes break down the basement membrane surrounding a solid tumor
thus allowing tumor cells to migrate to distant sites within the body and establish secondary
tumors. These secondary tumors are generally refractory to normal therapy. In order for both
the primary secondary tumors to be established they have to develop a blood supply. This
process of neovascularisation is known as angiogenesis.
1 Both metastasis and angiogenesis
are key targets for new drug discovery.
The use of in vitro human tumor cell lines, in vivo xenografts of human tumors, and molecular
mechanism and target directed screening are all proving to be valuable tools in the
discovery process for novel anticancer drugs.
Evaluation of Gold(Ill) Complexes
The discovery of the antitumor activity of cisplatin cis-[PtCI2(NH3)] in 1969 prompted the
continuing search for other metal-based drugs. Gold has been included in this search; and
there has been intensive effort to identify a gold antitumor drug.
’2 The main focus has been
on complexes of gold(I), particularly gold phosphine complexes such as [Au(dppe)] which
showed promising activity in a number of tumor models. In our own laboratory we adopted an
integrated approach to the search for new metal-based anticancer drugs, incorporating in
vitro screening, in vivo human tumor xenograft models, and mechanistic studies. The value of
this integrated approach is illustrated in a collaborative project with the Department of
Chemistry, UMIST, UK and the Institute of Cancer Research, UK, investigating the potential
antitumor activity of a class of gold(Ill) complexes see Parish, This volume pages_##).
Gold(Ill) is isoelectronic (d8) with platinum(ll) and likewise forms square planar complexes. It
is therefore tempting to speculate that such complexes would have similar antitumor activity
to cisplatin. Gold(Ill) complexes have not been as thoroughly investigated as gold(I)
complexes, primarily because of their reactivity. In order to stabilise the gold(Ill) oxidation
state in a reducing biological milieu we have synthesised complexes with a single
mononegative bidentate ligand, damp, (2-[(dimethylamino)methyl]phenyl), and two
monodentate anionic ligands e.g. CI or acetate, or bidentate ligands such as oxalate and
malonate (Figure 1).
3 The damp ligand forms part of a five-membered chelate ring in which
the nitrogen of the amine group and the carbon of the aryl ring bond to the metal. The
monodentate ligands are readily hydrolysed and are available for substitution.
4
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1" X=CI
/X
2 X=SCN
3 X=acetato AuX
4 X=oxalato
/ 5 X=malonato
Figure 1 Structures of Au(lll) 2-[(dimethylamino)methyl]phenyl complexes.
The compounds were first tested against two panels of human tumor cell lines. The primary
cell panel consisted of cells from tumors representative of different tissue types and with
different chemosensitivities to cisplatin (Table 2). Differential cytotoxicity, as opposed to
non-selective toxicity, was used as an indicator of potential antitumor actvity of test
compounds, The second panel was disease-oriented and consisted of cell lines established
from human ovarian tumors. This panel inr.iuded two pairs of cisplatin-sensitive and cisplatin-
resistant lines, with defined mechanisms of resistance (CHI/CH1-R, A2780/A2780-R), and
also two inherently resistant cell lines (HX62 and SK-OV-3). This panel has been used to
identify agents with the ability to circumvent cisplatin resistance (Table 3).
6
Table 2 Selective cytotoxicity (ICs0 pM) of cisplatin to the primary cell line panel.
SW620 SWi116 ZR75’i HT2i-219 HTi-376 -SK’oV’3 RANGE
COLON COLON BREAST COLON BLADDER OVARIAN (Lowest
ICo/Highest
167 163 27 7 23’ 2’13 9.8
Table 3 Cytotoxicity (ICs0 M) of cisplatin towards cisplatin sensitive and resistant ovarian
cell lines. Mechanisms of resistance are shown, numbers in parentheses represent
resistance factors of sensitive/resistant pairs (IC0 of resistant cell line:lCs0 of sensitive
cell line)
HX62 SK-OV-3 -CHl-- CH1-R- A2780 -A2780-R RANGE
Intracellular
detoxification
Decreased
drug
accumulation
5.2
Intracellular
detoxification
DNA da.mage
repair
0.12 0".56 (’4 7)’
DNA damage
1.2 10 (8.3)
Intracellular
detoxification
DNA damage
repair ......_...:repair
(Lowest ICso/
Highest ICs)
150
Most of the cell lines used can also be grown as solid tumor xenografts in immune-deprived,
nude, mice and thus allowing the compounds to be further evaluated in vivo against the
tumor types found to be sensitive in vitro. A typical tumor growth curve for the HT1376
bladder carcinoma is shown in Figure 2. The growth rate of this tumor is reduced by cisplatin
at a dose of 4.5 mg/kg, the maximum tolerated dose for cisplatin in this tumor model.
Initial in vitro studies indicated that the breast carcinoma cell line ZR-75-1 was sensitive to
[AuCl(damp)] (Table 4). This compound was then further tested in vivo against a xenograft
of the same tumor cells where it demonstrated modest antitumor activity, seen as a reduction
in tumor growth compared with controls, comparable to cisplatin. This prompted the
synthesis of further analogues with enhanced solubility in order to improve upon the
14,16 biological properties.
The activity of these analogues against the two cell line panels is shown in Tables 4 and 5.
The compounds exhibited a cytotoxicity profile similar to cisplatin against the primary cell
line panel with the HT1376 bladder carcinoma line being the most sensitive. Interestingly, in
the ovarian cell line lanel the compounds were equally active against the CHI/CH1-R
sensitive/resistant pair.
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Figure 2 Growth of the HT1376 bladder carcinoma cell line xenograft. Cisplatin was
administered i.p at 0, 7 14, and 21 days. Tumor growth is expressed as Relative Tumor
Volume,
(RTV 100(mean tumor volume at time of assessment)/(mean tumor volume at Day 0)
Table 4 Cyt0.toxicitY. (ICso pM) of AU(III) complexes towards primary tumor....c.ell line panel.
COMPOUND SW SW ZRL-75’1 HT29/2i HT1376 SK’OV-3 NGE
620 1116 9
[AuCI2(damp)] 124 119 2 7 5 5 3 0 4 5 4
[Au(SCN)2(damp)] 51 47 34 25 6.7 20 7.6
[Au(OAc)(damp)] 281 238 45 67 3 3 21.6
[Au(ox)(damp)] 205 215 41 19 10 10 21.5
[Au(mal)(damp)] 67 80 36 36 1 7.3
The complexes (with the exception of [Au(SCN)(damp)] which had poor solubility and had a
similar cytotoxicity profile to the other compounds therefore indicating no activity 6advantage
over the other complexes) were evaluated against the HT1376 tumor in vivo. Both the
malonato and acetato complexes were active against the HT1376 tumor (see Figures 3 and
4). The chloro complex was less active with the oxalato complex being inactive. This could
be explained by their lower solubilities in both water and octanol compared with the acetato
and malonato complexes. This poor solubility of the chloro and oxalato complexes would
reduce their absorption and limit their biodistribution. The acetato complex
[Au(acetato)(damp)] was also tested against a xenograft of the CH1 ovarian cell line. This
compound was also active against this xenograft, though the activity was significantly less
than that reported for cisplatin against the same tumor.
echanistic Studies
Mechanistic studies focused on the acetato complex (Figure 1). Cisplatin was included in the
studies in order to compare directly the mode of action of the structurally similar gold(Ill)
complexes. These studies examined the effects of [Au(acetato)(damp)] at the molecular
level by looking at possible interactions with DNA, at the cellular level, and at the
16 pharmacological level in both cell culture and animal models.
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Table 5 Cytotoxicity (ICs0M) of Au(lll) complexes towards ovarian tumor cell line panel.
COMPOUND HX6 SK-OV-3 CH1 CH1-R A2780 A2780-R RANGE
2
[AuCl(damp)] 57 109 13 22 (1.7) 8.2 47 (5.7) 13.3
[Au(SCN)=(damp)] 31 3 9 0 11 (1.1) 2.0 26 (13) 19.5
[Au(OAc)=(damp)] 34 107 12 (1.1) 3.5 35 (10) 31
[Au(ox)(damp)] 30 42 13 (1.2) 3.7 35 (9.5) 11.4
[Au(mal)(damp)] 27 30 2.7 3.3 (1.2) 2.7 16 (5.9) 11.1
H1!376 XENOGRAFT (a)
Treatment with Au(darnp)(acetato) complex
=, Control -,- 12.5 mgtk -e-- 25 mgtkg
E 1500
O >
o 1000
-> 500
0 7 14 21 28
Days
Figure 3 Growth of the HT1376 bladder carcinoma cell line xenograft after treatment with
[Au(damp)(acetato)] on Day 0, 7, 14, and 21. Tumor growth is expressed as Relative Tumor
Volume (RTV).
The molecular target for cisplatin is DNA.’8 Cisplatin can form both inter- and intra-strand
cross-links with DNA. The latter, primarily G-G cross-links, are thought to be the cytotoxic
lesion. The interaction of [Au(acetato)(damp)] with DNA was investigated using two
techniques, a plasmid mobility assay, and alkaline elution. The former monitors the
migration of a closed circular plasmid, Col E1 in these studies, on an agarose gel.
9 The
closed circular plasmid exists in two forms, a supercoiled, condensed form (RFII) and a
nicked relaxed form (RFI). The RFII form migrates faster than the RFI form on the gel.
Cisplatin, which can bind to the DNA, reduced the migration of the RFII form. This is due to
the induction of inter- and intra-strand cross-links causing unwinding, superwinding, and
rewinding of the DNA. The mobility of the RFI form was increased by similar interactions. For
[Au(acetato)(damp)] no effect was observed on plasmid mobility except at the highest
concentration, 1500 laM, 100 fold higher than the ICo against the HT1376 cells. This
concentration is so high as to be pharmacologically irrelevant, whereas in contrast cisplatin
exerted an effect at <10 tM.
The cross-linking of DNA strands can be assayed using a technique known as alkaline
elution. This is a filtration technique in which the formation of DNA cross-links impedes the
flow of DNA strands through a filter. This is further enhanced by performing the technique
under alkaline conditions, which separates DNA double strands into single strands.
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HT1376 XENOGRAFT (b)
Treatment with Au(damp)(rnalonato) complex
Control -,- 17.5 mgtk -’- 35 mglkg
150O
1000
Days
Figure 4 Growth of the HT1376 bladder carcinoma cell line xenograft after treatment with
[Au(damp)(malonato)] on Day 0, 7, 14, and 21. Tumor growth is expressed as Relative Tumor
Volume (RTV).
Figure 5a. Figure 5b.
I_EGEND
"
Untreated Control
[0 OOp.M ci;plain-,----i----
* 100M [Au(damp)(acetate)]
#, r_rad atd.-,c_n_t_r0_!_____________J
Figure 5 Alkaline elution studies in SK-OV-3 cells after exposure to 100 ILtM
[Au(damp)(acetato)2], or 100 pM cisplatin showing formation of (a) interstrand cross-links and
(b) DNA strand breaks.
The ovarian tumor cells, SK-OV-3 were incubated for 24 hours in the presence of 4C-
thymidine with either 100 pM cisplatin or 100 pM [Au(acetato)=(damp)]. Cells pre-incubated
with H-thymidine were included to provide an internal standard in the assay. These cells
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were subsequently irradiated to induce DNA strand breaks and included with the treated 14C-
labeled cells. The cells were lysed on the filters and samples collected and analyzed for
radioactivity. The results are shown in Figure 5. Cisplatin cross-linked the DNA as shown by
the slower rate of elution compared with untreated controls (Figure 5a). Strand-breakage was
seen in irradiated, cisplatin treated cells (Figure 5a). The gold complex did not induce DNA
cross-links, however there was some indication of DNA strand-breakage (Figure 5a) but this
was not evident in the subsequent experiment looking specifically for strand breakage (Figure
5b).
Further evidence that DNA may not be the target for the gold(Ill) complexes comes from
studies on the chemical interactions of these compounds with biological donor ligands. The
results indicated that the gold(Ill) damp complexes had a preference for S-donor ligands
such as glutathione and cysteine, with only limited reactivity against nucleosides and their
bases.
TM
At the cellular level cisplatin causes a block in the cell cycle at the point where DNA repair
occurs, the S/G2 interface. The stages of the cell cycle can be monitored using flow
cytometry. In this technique cells are fixed and stained with propidium iodide, a DNA
fluorochrome, which binds quantitatively to DNA. The degree of fluorescence is therefore
directly proportional to the DNA content of the cell, which in turn is an indicator of the
position of the cells in the cell cycle. The ovarian cell line, SK-OV-3 was incubated with
[Au(acetato)(damp)] for 4 hours at concentrations of either 30 l.tM or 100 pM and cell cycle
analysis determined from DNA content. Using this technique it was apparent that the gold(Ill)
complexes, unlike cisplatin, did not exert a cell cycle specific effect (Table 6).
Table 6 The effect of [Au(damp)(acetato)2] on the cell cycle of SK-OV-3 cells. The results
show the percentage of cells in the different stages of the cell cycle as determined by flow
_c_y_to__m____e_try__._
G1 S G2
CONTROL CELLS 43.3 41.6 15.1
30 #IVl 34.4 51.8 14.0
[Au(damp)(acetato)z]
100 pM 24.4 53.8 21.9
[_A_u...(da____p)(ac_e_tato)2]
The lack of a cell cycle specific effect was further supported by data from a study looking at
the rate of cell kill.The HT1376 bladder carcinoma cells were treated with either cisplatin
or [Au(acetato)=(damp)] for 4 hours over a concentration range of 0-200 pg/ml. Cell survival
was then assayed immediately post-dosing (0 hours) and 24, 48 and 72 hours post-dosing.
From a comparison of ICso values at different time points (Table 7) it is evident that cisplatin
toxicity is delayed, a result of the need for the cells to proceed through a replication cycle in
order for cisplatin to exert its effect, compared with [Au(acetato)=(damp)] where cell death
occurs rapidly after dosing.
Table 7 Rate of cell kill. The HT1376 cells were treated with test compound for 4 hours and
cell survival monitored at time intervals post-dosing. Results are expressed as ICo (lg/ml)
Time post-dosin9 (hours) IC0 Cisplatin ICo [Au(damp)(acetato)]
0 29
24 48 9.5
48 22 8.6
72 14 8.1
The molecular and cellular studies described above indicated that the Au(lll)(damp)
complexes were acting via a mechanism different to that of cisplatin. These observations
were further supported by the in vitro and in vivo pharmacological data. For example, in the
ovarian cell line panel the acetato analogue was equally active against the cisplatin
resistant cell line CH1R, as against its cisplatin sensitive counterpart, CH1. The mechanism
of resistance to cisplatin in this cell line is repair of cisplatin-induced DNA damage. Also
298S.P. Fricker Metal-Based Drugs
[Au(acetato)=(damp)] had little activity against the ADJ/PC6 murine tumor which is known to
16 be particularly sensitive to compounds which cross-link DNA, such as cisplatin.
Conclusion
It is now apparent that using murine leukemia models as screens for new anticancer drugs
has major limitations. This has led to a major reevaluation of tumor screening methodology.
The use of human tumor cell lines provides a valuable alternative strategy for identifying new
antitumor drugs, including metal-based agents. These cell lines, when incorporated into a
panel of selected cell lines, can be used as a primary in vitro screen. The ability of many of
these cell lines to be grown as xenografts in immune-deprived mice also allows them to be
used for in vivo evaluation. A mechanistic approach to drug discovery also provides new
opportunities for identifying novel agents and should form an integral part of any drug
discovery program.
We have adopted an integrated approach combining in vitro and in vivo tumor models, and
investigations into drug mechanism, to evaluate the potential antitumor activity of a class of
gold(Ill) complexes. We have shown that the square planar gold(Ill) complexes
[Au(acetato)(damp)] and [Au(malonato)(damp)] have activity against human tumor cells in
both in vitro and in vivo test systems. Detailed studies on their possible mechanism of action
at the molecular, cellular and pharmacological level, have shown that these compounds,
though superficially similar in structure to cisplatin, act via a quite different mechanism. This
observation in particular suggests that these compounds may represent a novel class of
metal-based antitumor agent.
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